ЭЛИМИНАЦИЯ РАКА ШЕЙКИ МАТКИ: ОПТИМИЗАЦИЯ НАЦИОНАЛЬНОЙ МОДЕЛИ СКРИНИНГА ДЛЯ УЗБЕКИСТАНА
Keywords:
Рак шейки матки, скрининг, ВПЧ-тестирование, самозабор (self-sampling), элиминация ракаAbstract
Цель работы: Обосновать необходимость оптимизации национальной программы скрининга рака шейки матки (РШМ) в Узбекистане в контексте глобальной стратегии ВОЗ по элиминации данного заболевания.
References
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/9789240014107
3. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Uzbekistan. Summary Report 2023. [Internet]. [Cited 2026 May].
4. Мусаева Н.Х., Хайдарова М.М. Эпидемиологические аспекты рака шейки матки в Узбекистане: анализ текущей ситуации. Журнал биомедицины и практики. 2023;3(2):45-52.
5. Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet. 2020;395(10224):591-603.
6. Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reached populations: ASCO Resource-Stratified Guideline. JCO Global Oncology. 2020;6:125-136.
7. Schiffman M, Wentzensen N, Wacholder S, et al. Human papillomavirus testing in the prevention of cervical cancer. Journal of the National Cancer Institute. 2011;103(5):368-383.
8. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: WHO; 2021.
9. Polman NJ, Ebisch RMF, Heideman DAM, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, comparative, non-inferiority trial. The Lancet Oncology. 2019;20(2):229-238.
10. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. European Journal of Cancer. 2009;45(15):2649-2658.
11. Zhao FH, Jeronimo J, Qiao YL, et al. An evaluation of Novaprep and Pap smear cytology versus HPV testing for screening in a target population in South China. International Journal of Cancer. 2014;134(8):1881-1892.
12. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287(18):2372-2381.
13. Dillner J, Rebolj M, Bais P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1242.
14. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524-532.
15. Wentzensen N, Schiffman M, Palmer T, et al. Performance of HPV testing, liquid-based cytology, and p16/Ki-67 dual stain cytology in primary screening. Journal of the National Cancer Institute. 2016;108(12):djw174.
16. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries in 2003: a cross-sectional study. The Lancet. 2008;371(9614):754-767.
17. Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Annals of Global Health. 2014;80(5):412-417.
18. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: a grand challenge in global health. The Lancet. 2017;389(10071):847-860.
19. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285(11):1500-1505.
20. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. New England Journal of Medicine. 2011;364(22):2096-2106.
21. Arbyn M, Castle PE. Offering self-sampling kits for HPV testing to reach women who do not attend in person. The Lancet Oncology. 2015;16(1):18-30.
22. Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reaching underscreened women by using HPV self-sampling: A systematic review and meta-analysis. The Lancet Oncology. 2018;19(10):1374-1385.
